Table 4 Ongoing phase 2 and 3 studies investigating late-line therapies in ovarian cancer
From: Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Agent | NCT # Study name | Phase | Est. N | Setting | Expected completion |
|---|---|---|---|---|---|
PARP Inhibitors | |||||
Niraparib | NCT02354586 QUADRA | 2 | 400 | Recurrent, ≥4th- 5th-line | October 2017 |
Olaparib | NCT02282020 SOLO-3 | 3 | 411 | Recurrent, ≥3rd-line | December 2017 |
Olaparib | NCT02889900 CONCERTO | 2 | 100 | Recurrent, ≥3rd-line | November 2018 |
Rucaparib | NCT01891344 ARIEL2 | 2 | 480 | Recurrent, ≥4th-line | March 2017 |
Rucaparib | NCT01968213 ARIEL3 | 3 | 540 | Recurrent, ≥3rd-line | March 2017 |
Mirvetuximab soravtansine (an antibody-drug conjugate targeting the folate-alpha receptor) | |||||
NCT02631876 FORWARDI | 3 | 333 | Platinum-resistant; 1–3 prior lines of chemotherapy | February 2019 | |
NUC-1031 (gemcitabine prodruga) | |||||
NCT03146663 | 2 | 64 | Platinum-resistant; ≥3 prior lines of chemotherapy | June 2020 | |
Trabectedin (novel alkylating chemotherapy agent) | |||||
NCT01846611 ORCHYD | 3 | 670 | Platinum-sensitive; 3rd line; known BRCA1/2 mutation | December 2019 | |
Ipilimumab (immune checkpoint inhibitor) | |||||
NCT01611558 | 2 | 49 | Platinum-sensitive; ≤4 prior lines of chemotherapy | July 2019 | |
Birinapant (SMAC mimetic and IAP inhibitor) | |||||
NCT02756130 | 2 | 34 | In combination with carboplatin in newly diagnosed or recurrent disease | June 2020 | |
Volasertib (Plk1 inhibitor) | |||||
In development; no ongoing phase 2 or phase 3 studies | |||||